“Greenwich LifeSciences Welcomes Prestigious Harvard and Johns Hopkins to Flamingo-01 Team”
Welcome to the Greenwich LifeSciences Blog! Exciting News for Breast Cancer Prevention STAFFORD, Texas, Jan. 23, 2025 (GLOBE NEWSWIRE) — Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced the initiation of…